Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Adenocarcinoma

Carcinoma, Renal Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Adagrasib

Tyrosine Kinase Inhibitors

Tyrosine

Patients with advanced solid tumors and the following:

* HRAS-mutant and/or amplified tumors (any solid tumor type)
* HRAS overexpression (only for HNSCC tumors)
* KRAS and/or NRAS and/or HRAS-mutant and/or amplified for NSCLC or CRC
* KRAS-mutant and/or amplified PDAC

Patients who have received at least 1 prior systemic therapy with IO-based treatment for locally advanced or metastatic RCC with predominantly clear cell subtype

Patients with KRAS G12C-mutant locally advanced or metastatic NSCLC who have received at least 1 prior systemic therapy for advanced or metastatic NSCLC

KO-2806

Cabozantinib

Clinical Operations

Xiomara Menendez, RN

Christopher Lim

Amy Whitaker

Nancy Olsen

Emily McClure, RN

Jessica Ley

Christina Caldwell

UW Carbone Cancer Center - Cancer Connect

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors

Area under the curve from time zero to last measurable concentration for KO-2806 (in the absence and presence of food) and combination agent.

Area under the curve from time zero to infinity post administration for KO-2806 (in the absence and presence of food) and combination agent

Maximum plasma concentration (Cmax) of KO-2806 (in the absence and presence of food) and the combination agent

Minimum plasma concentration (Cmin) of KO-2806 (in the absence and presence of food) and the combination agent

Time to maximal concentration (Tmax) of KO-2806 (in the absence and presence of food) and the combination agent

Estimated terminal elimination rate constant of KO-2806 and the combination agent

Half-life (t1/2) of KO-2806 (in the absence and presence of food) and the combination agent

Total apparent clearance (CL/F) of KO-2806 and the combination agent

Total apparent volume of distribution (Vd/F) of KO-2806 and the combination agent

QT interval corrected for heart rate (HR) using Fridericia's formula (QTcF) for KO-2806 monotherapy and in combination

Renal clearance of KO-2806 excretion in urine

Spots Global Cancer Trial Database for kras g12c inhibitor